Oculus Innovative Sciences Receives U.S. FDA Approval for Lasercyn™ for Use Following Laser Procedures, Microdermabrasions and Chemical Peels Apr 20, 2016
Oculus Innovative Sciences Receives European Approval to Market Sinudox™ Indicated for Use in Nasal Irrigation Apr 13, 2016
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of New Patents for Microcyn® Technology Apr 6, 2016
Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery Mar 30, 2016
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH® Animal Healthcare Products Mar 23, 2016
Oculus Innovative Sciences Announces Pricing of $3.4 Million Underwritten Public Offering Mar 18, 2016
Oculus Innovative Sciences Announces Proposed Underwritten Public Offering of Common Stock and Warrants Mar 17, 2016
Oculus Innovative Sciences to Present at the Roth Capital Partners 28th Annual Conference Mar 9, 2016
Oculus Innovative Sciences Receives European Approval to Market Lasercyn Indicated for Use Following Laser Skin Resurfacing Mar 3, 2016
